These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 29485707

  • 1. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
    Chorzalska A, Ahsan N, Rao RSP, Roder K, Yu X, Morgan J, Tepper A, Hines S, Zhang P, Treaba DO, Zhao TC, Olszewski AJ, Reagan JL, Liang O, Gruppuso PA, Dubielecka PM.
    Mol Oncol; 2018 May; 12(5):630-647. PubMed ID: 29485707
    [Abstract] [Full Text] [Related]

  • 2. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
    Busch C, Mulholland T, Zagnoni M, Dalby M, Berry C, Wheadon H.
    Cell Commun Signal; 2023 Nov 29; 21(1):342. PubMed ID: 38031192
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M.
    Yakugaku Zasshi; 2018 Nov 29; 138(12):1461-1466. PubMed ID: 30504658
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. PKC-β/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.
    Ma D, Liu P, Wang P, Zhou Z, Fang Q, Wang J.
    J Cell Physiol; 2021 Sep 29; 236(9):6312-6327. PubMed ID: 33561320
    [Abstract] [Full Text] [Related]

  • 7. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.
    Autophagy; 2015 Sep 29; 11(2):355-72. PubMed ID: 25701353
    [Abstract] [Full Text] [Related]

  • 8. BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
    Xu X, Zhang X, Liu Y, Yang L, Huang S, Lu L, Wang S, Guo Q, Zhao L.
    Oncotarget; 2016 Apr 26; 7(17):24436-54. PubMed ID: 27027438
    [Abstract] [Full Text] [Related]

  • 9. FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation.
    Yang T, Sim KY, Ko GH, Ahn JS, Kim HJ, Park SG.
    J Exp Clin Cancer Res; 2022 Mar 03; 41(1):82. PubMed ID: 35241148
    [Abstract] [Full Text] [Related]

  • 10. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M, Schnekenburger M, Losson H, Vermeulen K, Hahn H, Gérard D, Lee JY, Mazumder A, Ahamed M, Christov C, Kim DW, Dicato M, Bormans G, Han BW, Diederich M.
    Clin Epigenetics; 2020 May 19; 12(1):69. PubMed ID: 32430012
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V, Borgo C, Cesaro L, Pinna LA, Donella-Deana A.
    Oncotarget; 2016 Apr 05; 7(14):18204-18. PubMed ID: 26919095
    [Abstract] [Full Text] [Related]

  • 12. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
    Li X, Pang J, Xue W, Wang Y, Tian T, Elgehama A, Wu X, Wu X, Sun Y, Qiu H, Shen Y, Xu Q.
    Toxicol Appl Pharmacol; 2018 Dec 01; 360():249-256. PubMed ID: 30290167
    [Abstract] [Full Text] [Related]

  • 13. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
    Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA.
    Tumour Biol; 2016 Sep 01; 37(9):12643-12654. PubMed ID: 27444277
    [Abstract] [Full Text] [Related]

  • 14. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.
    Huang G, Yin Z, Wang X, Wen Z, Su R, Li C, Liu Y, Yang J, Hu H, Nie H, Zeng X, Fei J.
    Phytomedicine; 2023 Aug 01; 117():154918. PubMed ID: 37329755
    [Abstract] [Full Text] [Related]

  • 15. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
    Ben-Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus JL, Rankin S, Clark RE, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf TH, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason GV, Holyoake TL, Loges S.
    Clin Cancer Res; 2017 May 01; 23(9):2289-2300. PubMed ID: 27856601
    [Abstract] [Full Text] [Related]

  • 16. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C, Bianchini M, Bengió R, Larripa I.
    Blood Cells Mol Dis; 2014 May 01; 52(2-3):121-5. PubMed ID: 24091144
    [Abstract] [Full Text] [Related]

  • 17. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
    Mancini M, De Santis S, Monaldi C, Bavaro L, Martelli M, Castagnetti F, Gugliotta G, Rosti G, Santucci MA, Martinelli G, Cavo M, Soverini S.
    J Exp Clin Cancer Res; 2019 May 23; 38(1):216. PubMed ID: 31122263
    [Abstract] [Full Text] [Related]

  • 18. Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia.
    Su R, Wen Z, Zhan X, Long Y, Wang X, Li C, Su Y, Fei J.
    Cell Death Dis; 2024 Aug 23; 15(8):615. PubMed ID: 39179585
    [Abstract] [Full Text] [Related]

  • 19. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 20. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L, Wang H, Zhu X, Liu W, Zhou S, Geng Z, Xiao Y, Zou P, You Y, Li Q, Zhu X.
    Stem Cells Dev; 2019 Nov 15; 28(22):1480-1485. PubMed ID: 31530245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.